Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of CCX168 in Healthy Volunteers
NCT05984251Phase 1Completed
- Sponsor
- Amgen
- Start
- Dec 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of avacopan in vasculitis and systemic lupus erythematosus (SLE) (5 cohorts), sponsored by Amgen. Primary endpoints: Number of Participants Experiencing Adverse Events (AEs) up to 43 days, Number of Participants Experiencing Clinically Significant Changes in Laboratory Parameters up to 29 days and 2 more. Started Dec 2009; status: completed.
02
Drugs
avacopan
03
Conditions
vasculitissystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05984251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984251.